@article{TCR12472,
author = {John Dimitriadis and Aristotelis Bamias},
title = {Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {More than 200,000 people worldwide are diagnosed with renal-cell carcinoma (RCC) each year, and almost one third of them will die from metastatic disease (1). Although 5-year survival rate for metastatic disease has increased from 34% in 1954 to 73% in 2011, it still remains low (8–10%) in metastatic setting (2). Although nephrectomy can be curative for the majority of patients presenting with localized disease, nearly 40% of patients initially diagnosed with stages II and III, will eventually relapse (3). Taking the above into consideration, development of an effective adjuvant treatment for patients in high-risk for relapse following nephrectomy is needed.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/12472}
}